"aromatase inhibitor therapy" trang 2 - tải miễn phí từ tailieunhanh
Báo cáo Y học: Study of substrate specificity of human aromatase by site directed mutagenesis

Báo cáo Y học: Study of substrate specificity of human aromatase by site directed mutagenesis
13    85    0
Báo cáo Y học: Dietary bisphenol A prevents ovarian degeneration and bone loss in female mice lacking the aromatase gene (Cyp19 )

Báo cáo Y học: Dietary bisphenol A prevents ovarian degeneration and bone loss in female mice lacking the aromatase gene (Cyp19 )
9    66    0
Progesterone receptor modulators in breast cancer

Progesterone receptor modulators in breast cancer
14    105    0
Effect of intrauterine insemination on women with polycystic ovary syndrome stimulated by letrozole

Effect of intrauterine insemination on women with polycystic ovary syndrome stimulated by letrozole
6    74    0
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: Results of the prospective observational EvAluate-TM study

Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: Results of the prospective observational EvAluate-TM study
9    86    0
Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: Study protocol for a randomized controlled trial

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: Study protocol for a randomized controlled trial
7    54    1
An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: The ERA project

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: The ERA project
11    79    1
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer

Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer
11    43    1
Can we use gonadotropin plasma concentration as surrogate marker for BMIrelated incomplete estrogen suppression in breast cancer patients receiving anastrozole?

Can we use gonadotropin plasma concentration as surrogate marker for BMIrelated incomplete estrogen suppression in breast cancer patients receiving anastrozole?
7    50    1
Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells

Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells
16    84    1
Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormonesensitive breast cancer

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormonesensitive breast cancer
11    30    1
Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy
9    70    1
Adherence to hormone therapy among women with breast cancer

Adherence to hormone therapy among women with breast cancer
8    59    1
FemZone trial: A randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

FemZone trial: A randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
11    53    1
Examestane in advanced or recurrent endometrial carcinoma: A prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

Examestane in advanced or recurrent endometrial carcinoma: A prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
7    37    1
Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)

Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
5    56    1
Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice

Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice
13    35    1
Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer

Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer
12    95    1
Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptorpositive advanced breast cancer

Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptorpositive advanced breast cancer
12    45    1
Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer

Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer
12    9    1